Insider Transactions in Q4 2016 at Merck & Co., Inc. (MRK)
Insider Transaction List (Q4 2016)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
133,920
-20.83%
|
$8,704,800
$65.03 P/Share
|
|
Nov 10
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
133,920
+17.24%
|
$3,080,160
$23.45 P/Share
|
|
Nov 09
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
6,080
-1.18%
|
$395,200
$65.0 P/Share
|
|
Nov 09
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
6,080
+1.17%
|
$139,840
$23.45 P/Share
|
|
Nov 07
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
85,523
-68.62%
|
$5,131,380
$60.02 P/Share
|
|
Nov 07
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,523
+21.69%
|
$3,420,920
$40.28 P/Share
|
|
Nov 02
2016
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$295,000
$59.5 P/Share
|
|
Nov 02
2016
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$255,000
$51.86 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
SELL
Open market or private sale
|
Direct |
20,000
-81.32%
|
$1,180,000
$59.06 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.25%
|
$740,000
$37.35 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
40,800
-31.63%
|
$2,529,600
$62.07 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
40,800
+24.03%
|
$1,795,200
$44.19 P/Share
|